- Home
- ATAI vs GMRE Comparison
ATAI vs GMRE Comparison
Compare ATAI & GMRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- GMRE
- Stock Information
- Founded
- ATAI 2018
- GMRE 2011
- Country
- ATAI Germany
- GMRE United States
- Employees
- ATAI N/A
- GMRE N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- GMRE Real Estate Investment Trusts
- Sector
- ATAI Health Care
- GMRE Real Estate
- Exchange
- ATAI Nasdaq
- GMRE Nasdaq
- Market Cap
- ATAI 444.7M
- GMRE 485.5M
- IPO Year
- ATAI 2021
- GMRE N/A
- Fundamental
- Price
- ATAI $3.48
- GMRE $6.84
- Analyst Decision
- ATAI Strong Buy
- GMRE Buy
- Analyst Count
- ATAI 3
- GMRE 3
- Target Price
- ATAI $11.67
- GMRE $10.38
- AVG Volume (30 Days)
- ATAI 8.9M
- GMRE 740.7K
- Earning Date
- ATAI 08-12-2025
- GMRE 08-05-2025
- Dividend Yield
- ATAI N/A
- GMRE 11.97%
- EPS Growth
- ATAI N/A
- GMRE N/A
- EPS
- ATAI N/A
- GMRE 0.03
- Revenue
- ATAI $1,863,000.00
- GMRE $138,220,000.00
- Revenue This Year
- ATAI $423.05
- GMRE $4.47
- Revenue Next Year
- ATAI N/A
- GMRE $3.60
- P/E Ratio
- ATAI N/A
- GMRE $219.31
- Revenue Growth
- ATAI 572.56
- GMRE N/A
- 52 Week Low
- ATAI $1.03
- GMRE $6.06
- 52 Week High
- ATAI $4.00
- GMRE $10.46
- Technical
- Relative Strength Index (RSI)
- ATAI 60.69
- GMRE 52.75
- Support Level
- ATAI $3.06
- GMRE $6.75
- Resistance Level
- ATAI $3.70
- GMRE $7.28
- Average True Range (ATR)
- ATAI 0.27
- GMRE 0.15
- MACD
- ATAI 0.00
- GMRE -0.04
- Stochastic Oscillator
- ATAI 52.46
- GMRE 51.89
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About GMRE Global Medical REIT Inc.
Global Medical REIT Inc is engaged predominantly in the acquisition of purpose-built healthcare facilities and the leasing of those facilities to physician groups and regional and national healthcare systems. The company's principal business objective is to provide attractive, risk-adjusted returns to its stockholders through a combination of reliable dividends and long-term capital appreciation. Its healthcare facilities are located in secondary markets and suburbs of primary markets and are typically leased to single-tenants under triple-net leases.